Bicocca Open Archive

Logo unimib boa
QUARTI TREVANO, FOSCA ANNA LUISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.466
EU - Europa 4.898
AS - Asia 2.132
SA - Sud America 21
AF - Africa 14
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 7
Totale 17.545
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.319
DE - Germania 896
SE - Svezia 836
IT - Italia 830
SG - Singapore 830
CN - Cina 683
IE - Irlanda 668
RU - Federazione Russa 579
UA - Ucraina 412
HK - Hong Kong 340
GB - Regno Unito 234
CA - Canada 140
FI - Finlandia 124
AT - Austria 96
VN - Vietnam 73
ID - Indonesia 56
FR - Francia 54
IN - India 53
DK - Danimarca 40
NL - Olanda 40
TR - Turchia 25
BE - Belgio 24
JP - Giappone 22
CZ - Repubblica Ceca 21
BR - Brasile 15
IR - Iran 12
PH - Filippine 8
AU - Australia 7
KR - Corea 7
RO - Romania 7
MK - Macedonia 5
ES - Italia 4
EU - Europa 4
LT - Lituania 4
TW - Taiwan 4
CL - Cile 3
HU - Ungheria 3
KE - Kenya 3
LK - Sri Lanka 3
MU - Mauritius 3
MX - Messico 3
MY - Malesia 3
PE - Perù 3
PL - Polonia 3
PT - Portogallo 3
BD - Bangladesh 2
BG - Bulgaria 2
BH - Bahrain 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
GD - Grenada 2
GR - Grecia 2
HR - Croazia 2
MG - Madagascar 2
NG - Nigeria 2
RS - Serbia 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BY - Bielorussia 1
ET - Etiopia 1
GE - Georgia 1
IL - Israele 1
LV - Lettonia 1
MD - Moldavia 1
MN - Mongolia 1
NO - Norvegia 1
PK - Pakistan 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
UG - Uganda 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 17.545
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.182
Fairfield 986
Woodbridge 936
Houston 694
Singapore 686
Frankfurt am Main 640
Dublin 632
Chandler 572
Wilmington 504
Ashburn 482
Jacksonville 466
Seattle 358
Hong Kong 338
Dearborn 317
Cambridge 307
New York 269
Princeton 246
Santa Clara 231
Milan 214
Lawrence 121
Altamura 120
Nanjing 113
Shanghai 98
Vienna 93
Beijing 87
Lachine 73
San Diego 67
Boardman 54
Jakarta 51
Lissone 50
Dong Ket 44
Andover 42
Helsinki 42
Guangzhou 39
Nanchang 38
Hebei 31
Toronto 26
Changsha 25
Fremont 25
Tianjin 25
Falls Church 24
London 22
Ningbo 22
Rome 22
Shenyang 22
Brussels 21
Jiaxing 21
Brno 20
Jinan 20
Munich 20
Cinisello Balsamo 18
Kunming 18
Ottawa 18
Mountain View 16
Hangzhou 15
Norwalk 15
San Mateo 15
Huizen 14
Monza 14
Auburn Hills 13
Nürnberg 13
Sacramento 13
Zhengzhou 12
Hefei 11
Los Angeles 11
Philadelphia 9
Lappeenranta 8
Monmouth Junction 8
Moscow 8
Padova 8
Pune 8
São Paulo 8
Vimercate 8
Edmonton 7
Groningen 7
Leawood 7
Busto Arsizio 6
Detroit 6
Esslingen am Neckar 6
Fuzhou 6
Kiev 6
Malgesso 6
New Delhi 6
Redmond 6
San Francisco 6
Winnipeg 6
Akatsuka-shinmachi 5
Amsterdam 5
Carate Brianza 5
Chicago 5
Dallas 5
Desio 5
Hounslow 5
Kyiv 5
Phoenix 5
Sovico 5
St Petersburg 5
University Park 5
Assago 4
Bari 4
Totale 12.968
Salva come PNG Salva come JPEG
Nome #
Heart rate as a sympathetic marker during acute adrenergic challenge 305
Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia 261
Sympathetic Neural Overdrive in the Obese and Overweight State: Meta-Analysis of Published Studies 246
Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction. 231
Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population 205
Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms 193
Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome 191
Sympathetic and baroreflex abnormalities in the uncomplicated prediabetic state 189
Sustained sympathoinhibitory effects of cardiac resynchronization therapy in severe heart failure 188
Sympathetic overdrive in the metabolic syndrome: meta-analysis of published studies 188
Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values 186
Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis 185
Reliability of heart rate as neuroadrenergic marker in the metabolic syndrome. 184
Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease 183
Iron Overload Increases Sympathetic Nervous Activity: Study in Hemochromatosis Patients at Diagnosis and Iron Depletion 183
Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study 182
Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study 181
Multiple sampling improves norepinephrine reproducibility in essential hypertension: a comparison with the microneurographic technique 176
Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan 176
Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity 174
Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study 174
Threshold and Target for Blood Pressure Lowering in the Elderly 173
Prevalence of cardiovascular risk factors in an unselected Italian population. Results of the CardioLab Project 2004-2008 172
Neurogenic abnormalities in masked hypertension 171
Incident Left Ventricular Hypertrophy in Masked Hypertension 170
Short- and long-term neuroadrenergic effects of moderate dietary sodium restriction in essential hypertension 169
Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: Results of a double-blind randomized multicentre trial 167
Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study 166
Sympathetic nerve traffic and baroreflex function in optimal, normal, and high-normal blood pressure states 166
Effects of hypertension and obesity on the sympathetic activation of heart failure patients 165
Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives 165
Hypertension, antihypertensive treatment and stroke prevention 162
Sympathetic Nerve Traffic and Arterial Baroreflex Function in Apparent Drug-Resistant Hypertension 162
Cardiovascular risk and adrenergic overdrive in the metabolic syndrome 161
Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials 159
Iron overload exerts sympathoexcitatory effects in men with essential hypertension: microneurogtaphic evidence 157
Neuroadrenergic activation in obstructive sleep apnoea syndrome: A new selectedmeta-analysis - revisited 156
Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes 155
The PAMELA (Pressioni Arteriose Monitorate E Loro Associazioni) study: Main features and results 155
Follow-up of Antihypertensive Therapy Improves Blood Pressure Control: Results of HYT (HYperTension survey) Follow-up 155
Autonomic Cardiovascular Alterations in Chronic Kidney Disease: Effects of Dialysis, Kidney Transplantation, and Renal Denervation 154
Response to possible difference in the sympathetic activation on extreme dippers with or without exaggerated morining surge 153
Baroreflex function in hypertension: consequences for antihypertensive therapy 152
Sympathetic neural abnormalities in type 1 and type 2 diabetes: a systematic review and meta-analysis 151
Total cardiovascular risk, blood pressure variability and adrenergic overdrive in hypertension: evidence, mechanisms and clinical implications 149
Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction 147
Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events 146
Multicentre randomised, double blind, evaluation of nebivolol plus HCTZ and irbesartan plus HCTZ in the treatment of systolic hypertension in the elderly: the NEHIS Study 145
Reinforcement of the adrenergic overdrive in the metabolic syndrome complicated by obstructive sleep apnea 144
HYT-Hypertension in Turkey: A Cross-Sectional Survey on Blood Pressure Control with Calcium Channel Blockers Alone or Combined with Other Antihypertensive Drugs 142
Should white-coat hypertension in diabetes be treated? Pro 140
Blood pressure control in resistant hypertension: new therapeutic options 139
Diurnal blood pressure variation and sympathetic activity 138
Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction 136
Blood pressure control and therapeutic modulation of the adrenergic overdrive 136
Heart Rate, Sympathetic Cardiovascular Influences, and The Metabolic Syndrome 135
Pheochromocytoma as a Clinical Model of Peripheral Sympathetic Overdrive: Old and New Findings 135
Clinical correlates and subclinical cardiac organ damage in different extreme dipping patterns 135
Salt intake and sympathetic activity - Response 133
Sympathetic activation in congestive heart failure: an updated overview 133
The 'neuroadrenergic hypothesis' in hypertension: current evidence 132
Adrenergic and metabolic effects of bariatric surgey in obese subjects: a longitudinal study 132
Response to sympathetic activity, heart failure, obesity, and metabolic syndrome: Is there any role for obstructive sleep apnea? 131
Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension 131
Left ventricular hypertrophy in isolated and dual masked hypertension 131
Early sympathetic activation in the initial clinical stages of chronic renal failure 130
The "J curve" problem revisited: old and new findings 130
Left ventricular mass reduction and hypertrophy regression following renal artery revascularization: a meta-analysis 130
Association between ADRA1A gene and the metabolic syndrome: candidate genes and functional counterpart in the PAMELA population 129
Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension 125
Sympathetic neural overdrive in congestive heart failure and its correlates: systematic reviews and meta-analysis 125
Sympathetic activation in congestive heart failure: Evidence, consequences and therapeutic implications 124
Early sympathetic activation in mild renal failure 123
4C.07:Relationships between cognitive dysfunction, clinic and ambulatory blood pressure and blood pressure variability: results from the PAMELA Study 122
Sympathetic activation in congestive heart failure: Reproducibility of neuroadrenergic markers 121
Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives 120
The importance of pulse pressure on cardiovascular risk and total mortality in the general population: Is sex relevant? 120
Blood pressure lowering effects of Rimonabant in obesità-related hypertension 118
Blood pressure control and antihypertensive treatment 118
Long-term changes in left ventricular mass echocardiographic findings from a general population 118
Long-term risk of sustained hypertension in white-coat or masked hypertension 117
Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity 117
Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project 115
Limited reliability of heart rate as a sympathetic marker in chronic kidney disease 113
Essential hypertension and the sympathetic nervous system 111
Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension 110
Muscle and skin sympathetic nerve traffic during physician and nurse blood pressure measurement 110
DIFFERING EFFECTS OF RENAL DENERVATION ON BLOOD PRESSURE AND SYMPATHETIC NERVE TRAFFIC: A SYSTEMATIC REVIEW AND META-ANALYSIS 109
Left ventricular mass and incident out-of-office hypertension in a general population 109
Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study 108
Uric acid and risk of new-onsetmetabolic syndrome, impaired fasting glucose and diabetesmellitus in a general Italian population: data from the Pressioni ArterioseMonitorate E Loro Associazioni study 107
The PAMELA research project: a 25-year long journey 107
Short- and Long-Term Reproducibility of Nighttime Blood Pressure Phenotypes and Nocturnal Blood Pressure Reduction 106
Long QT interval and malignant ventricular arrhythmia during treatment with cisapride. Report of a clinical case 105
Behaviour of regional sympathetic nerve traffic in obstructive sleep apnea syndrome 105
Sympathetic Neural Mechanisms Underlying Attended and Unattended Blood Pressure Measurement 102
Adverse prognostic value of persistent office blood pressure elevation in White coat Hypertension 101
Antihypertensive treatment and stroke prevention: From recent meta-analyses to the PRoFESS trial 98
Heart rate as a predictor of cardiovascular risk 98
Differential sympathetic activation in muscle and skin neural districts in the metabolic syndrome 95
Totale 14.783
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.573
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.552 0 0 0 0 0 331 354 203 276 159 167 62
2020/20212.492 155 147 209 259 175 221 220 239 186 293 140 248
2021/20222.063 165 171 263 201 177 162 110 83 110 128 195 298
2022/20232.814 320 813 274 271 165 453 48 157 159 20 89 45
2023/20242.231 56 56 112 120 298 501 387 74 252 67 51 257
2024/20252.242 321 721 250 268 518 164 0 0 0 0 0 0
Totale 18.134